Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status.
Rosha Babapour MofradPhilip ScheltensSangYun KimSungmin KangYoung Chul YounSeong Soo A AnJori TomassenBart N M van BerckelPieter Jelle VisserWiesje M van der FlierCharlotte E TeunissenPublished in: Alzheimer's research & therapy (2021)
Plasma MDS-OAβ combined with APOEe4 and age accurately identifies brain amyloidosis in a large Aβ-confirmed population. Using plasma MDS-OAβ as a screener reduced the costs and number of PET scans needed to screen for amyloidosis, which is relevant for clinical trials. Additionally, plasma MDS-OAβ levels appeared affected by long-term storage duration, which could be of interest for others measuring plasma Aβ biomarkers.